These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. CDKN2A mutations in multiple primary melanomas. Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223 [TBL] [Abstract][Full Text] [Related]
3. The CDKN2A tumor-suppressor locus--a tale of two proteins. Clurman BE; Groudine M N Engl J Med; 1998 Mar; 338(13):910-2. PubMed ID: 9516230 [No Abstract] [Full Text] [Related]
4. Role of the CDKN2A locus in patients with multiple primary melanomas. Puig S; Malvehy J; Badenas C; Ruiz A; Jimenez D; Cuellar F; Azon A; Gonzàlez U; Castel T; Campoy A; Herrero J; Martí R; Brunet-Vidal J; Milà M J Clin Oncol; 2005 May; 23(13):3043-51. PubMed ID: 15860862 [TBL] [Abstract][Full Text] [Related]
5. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants. Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182 [TBL] [Abstract][Full Text] [Related]
6. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study. Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB; Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043 [TBL] [Abstract][Full Text] [Related]
7. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641 [TBL] [Abstract][Full Text] [Related]
8. CDKN2A mutation and deletion status in thin and thick primary melanoma. Cachia AR; Indsto JO; McLaren KM; Mann GJ; Arends MJ Clin Cancer Res; 2000 Sep; 6(9):3511-5. PubMed ID: 10999737 [TBL] [Abstract][Full Text] [Related]
9. [From gene to disease; from p16 to melanoma]. Gruis NA; Bergman W Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670 [TBL] [Abstract][Full Text] [Related]
10. Two p16 (CDKN2A) germline mutations in 30 Israeli melanoma families. Yakobson E; Shemesh P; Azizi E; Winkler E; Lassam N; Hogg D; Brookes S; Peters G; Lotem M; Zlotogorski A; Landau M; Safro M; Shafir R; Friedman E; Peretz H Eur J Hum Genet; 2000 Aug; 8(8):590-6. PubMed ID: 10951521 [TBL] [Abstract][Full Text] [Related]
12. High prevalence of germline CDKN2A mutations in Slovenian cutaneous malignant melanoma families. Hocevar M; Avbelj M; Perić B; Zgajnar J; Besić N; Battelino T Croat Med J; 2006 Dec; 47(6):851-4. PubMed ID: 17167857 [TBL] [Abstract][Full Text] [Related]
13. Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation. Eliason MJ; Hansen CB; Hart M; Porter-Gill P; Chen W; Sturm RA; Bowen G; Florell SR; Harris RM; Cannon-Albright LA; Swinyer L; Leachman SA Arch Dermatol; 2007 Nov; 143(11):1409-12. PubMed ID: 18025365 [TBL] [Abstract][Full Text] [Related]
14. Germline mutations in CDKN2A are infrequent in female patients with melanoma and breast cancer. Nagore E; Montoro A; García-Casado Z; Botella-Estrada R; Insa A; Lluch A; López-Guerrero JA; Guillén C Melanoma Res; 2009 Aug; 19(4):211-4. PubMed ID: 19571771 [TBL] [Abstract][Full Text] [Related]
15. CDKN2A/CDK4 molecular study on 155 Italian subjects with familial and/or primary multiple melanoma. Majore S; De Simone P; Crisi A; Eibenschutz L; Binni F; Antigoni I; De Bernardo C; Catricalà C; Grammatico P Pigment Cell Melanoma Res; 2008 Apr; 21(2):209-11. PubMed ID: 18363633 [No Abstract] [Full Text] [Related]
16. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M; J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564 [TBL] [Abstract][Full Text] [Related]
17. Multiple primary melanoma revisited. Blackwood MA; Holmes R; Synnestvedt M; Young M; George C; Yang H; Elder DE; Schuchter LM; Guerry D; Ganguly A Cancer; 2002 Apr; 94(8):2248-55. PubMed ID: 12001124 [TBL] [Abstract][Full Text] [Related]
18. CDKN2A as a uveal and cutaneous melanoma susceptibility gene. Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702 [TBL] [Abstract][Full Text] [Related]
19. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families. Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491 [TBL] [Abstract][Full Text] [Related]
20. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma. Stratigos AJ; Yang G; Dimisianos R; Nicolaou V; Stefanaki I; Katsambas AD; Tsao H J Invest Dermatol; 2006 Feb; 126(2):399-401. PubMed ID: 16374456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]